Post doc position in the USA

January 9, 2012

A Postdoc position is proposed for 2 to 3 years, located in US with a collaborative work between MedImmune Company through R Herbst (US) and Inserm through D Damotte (France).

The objective of the project is to analyse the modulation of lung anti-tumor immune responses by COPD-associated chronic inflammation.

The post doc will develop and implement mouse models of COPD and lung cancer.  Importantly, these models will be combined to investigate the direct impact of COPD and underlying inflammation on lung tumor development. These models will also be used to determine if/how lung tumour changes the COPD-associated inflammatory environment and vice versa.  The project is part of a global study including a human part which will be conducted in Paris (France) in collaboration with another postdoc already recruited.

Applicants should have interest in immunity and cancer, and if possible aware of mouse manipulation.
The beginning of the project is January 2012 but may be flexible beyond 1 to 2 months.
Applications should include a CV and a letter explaining the field of interest. Letters of reference may be useful.
Please send application to Pr Diane Damotte, UMRS 872, Cordeliers Research Centre, 15 Rue de l’Ecole de Médecine 75006 Paris, France. diane.damotte@htd.aphp.fr
or to Dr Ronald Herbst : herbstro@medimmune.com

More News

Koç University Transplant Immunology Research Center – Open Position

September 10, 2020

Invite to Register Details in African Scientists Directory

July 24, 2020

IUIS Anti-Racism Statement

July 16, 2020

Share Immunology with your family and friends!

July 7, 2020

Global Science TV – Participate in the Public Value of Science project

June 29, 2020

African Scientists Directory

June 29, 2020

We have a winner! 2020 Early Career Research Prize in Vaccinology R&D

May 18, 2020Vaccine Committee (VAC)

2020 Edition: Day of Immunology

April 30, 2020

Menarini Prize for Outstanding Woman Immunologist

April 29, 2020Gender Equality Committee (GEC)